An Unexpected Transient Breakdown of the Blood Brain Barrier Triggers Passage of Large Intravenously Administered Nanoparticles

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Smith, Nicole M ^a   Gachulincova, Ivana ^a   Ho, Diwei ^a   Bailey, Charlotte ^a   Bartlett, Carole A ^a   Norret, Marck ^a   Murphy, John ^a   Buckley, Alysia ^a   Rigby, Paul J ^a   House, Michael J ^a   St Pierre, Timothy ^a   Fitzgerald, Melinda ^a   Iyer, K Swaminathan ^a   Dunlop, Sarah A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NANOPARTICLE; POLYMER;

ANIMAL; BLOOD BRAIN BARRIER; BRAIN DISEASES; DISEASE MODEL; FEMALE; HUMAN; INBRED RAT STRAIN; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; OPTIC NERVE; OPTIC NERVE INJURY; PATHOLOGY; PATHOPHYSIOLOGY; RAT; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL;

ADMINISTRATION, INTRAVENOUS; ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN DISEASES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; NANOPARTICLES; OPTIC NERVE; OPTIC NERVE INJURIES; POLYMERS; RATS; RATS, INBRED STRAINS; TISSUE DISTRIBUTION;

EID: 84960424249     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep22595     Document Type: Article

References (37)

1. Pardirdge, W. M. Blood-brain barrier delivery. Drug Discov Today. 12, 54-61 (2007).
2. Nance, E. A. et al. A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within Brain tissue. Sci. Transl. Med. 4, 149ra119 (2012).
3. Koffie, R. M. et al. Nanoparticles Enhance Brain Delivery of Blood-brain Barrier-Impermeable Probes for in Vivo Optical and Magnetic Resonance Imaging. Proc. Natl. Acad. Sci. 108(46), 18837-42 (2011).
4. Kreuter, J. et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target. 10(4), 317-325 (2002).
5. Wiley, D. T., Webster, P., Gale, A. & Davis, M. E. Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. Proc. Natl. Acad. Sci. 110(21), 8662-8667 (2013).
6. Lu, W., Wan, J., She, Z. & Jiang, X. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. J Control Release 118, 38-53 (2007).
7. Rao, K. S., Reddy, M. K., Horning, J. L. & Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials 29, 4429-4438 (2008).
8. Kratz, F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 132, 71-183 (2008).
9. Pardirdge, W. M. Drug transport across the blood-brain barrier. J. Cereb. Blood Flow Metab. 32, 1959-1972 (2012).
10. Weiss, N., Miller, F., Cazaubon, S. & Couraud, P. O. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta. 1788, 842-857 (2009).
11. Tornheim, P. A., Prioleau, G. R. & McLaurin, R. L. Acute responses to experimental blunt head trauma. Topography of cerebral cortical edema. J. Neurosurg. 60, 473-480 (1984).
12. Wang, J., Hamm, R. J. & Povlishock, J. T. Traumatic axonal injury in the optic nerve: evidence for axonal swelling, disconnection, dieback, and reorganization. J. Neurotrauma. 28, 1185-1198 (2011).
13. Chan, P. H., Schmidley, J. W., Fishman, R. A. & Longar, S. M. Brain injury, edema, and vascular permeability changes induced by oxygen-derived free radicals. Neurology. 34, 315-320 (1984).
14. Steinman, L. Elaborate interactions between the immune and nervous systems. Nat. Immunol. 5, 575-581 (2004).
15. Kerschensteiner, M., Stadelmann, C., Dechant, G., Wekerle, H. & Hohlfeld, R. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol. 53, 292-304 (2003).
16. Moalem, G. et al. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med. 5, 49-55 (1999).
17. Fitzgerald, M., Bartlett, C. A., Harvey, A. R. & Dunlop, S. A. Early events of secondary degeneration after partial optic nerve transection: an immunohistochemical study. J Neurotrauma. 27, 439-452 (2010).
18. Fitzgerald, M. et al. Secondary retinal ganglion cell death and the neuroprotective effects of the calcium channel blocker lomerizine. Invest Ophthalmol Vis Sci. 50, 5456-5462 (2009).
19. Tennant, M. & Beazley, L. D. A breakdown of the blood-brain barrier is associated with optic nerve regeneration in the frog. Visual Neuroscience. 9, 149-155 (1992).
20. Vargas, M. E. & Barres, B. A. Why Is Wallerian Degeneration in the CNS So Slow? Annu. Rev. Neurosci. 30, 153-179 (2007).
21. Nahirnay, P. C., Reeson, P. & Brown C. E. Ultrastructural analysis of blood-brain barrier breakdown in the peri-infarct zone in young adult and aged mice. J. Cereb. Blood Flow Metab. 36, 413-425 (2016).
22. Mollgard, K. & Saunders, N. R. The development of the human blood-brain and blood-CSF barriers. Neuropathol. Appl. Neurobiol. 12, 337-358 (1986).
23. Butt, A. M., Jones, H. C. & Abbott, N. J. Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J. Physiol. (Lond) 429, 47-62 (1990).
24. Del Valle, J., Camins, A., Pallas, M., Vilaplana, J. & Pelegri, C. A new method for determining blood-brain barrier integrity based on intracardiac perfusion of an Evans Blue-Hoechst cocktail. J. Neurosci. Methods. 174, 42-49 (2008).
25. Laterra, J., Keep, R., Betz, L. A. & Goldstein, G. W. Blood-Brain Barrier In Siegel, G. J., Agranoff, B. W., Albers, R. W. (eds), Basic Neurochemistry: Molecular, Cellular and Medical Aspects, 6th edition. Philadelphia: Lippincott-Raven (1999).
26. Ballabh, P., Braun, A. & Nedergaard, M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis. 16, 1-13 (2003).
27. Beggs, S., Liu, X. J., Kwan, C. & Salter, M. W. Peripheral nerve injury and TRPV1-expressing primary afferent C-fibers cause opening of the blood-brain barrier. Mol Pain. 6, doi: 10.1186/1744-8069-6-74 (2010).
28. Liu, J., Jin. X., Liu, K. J. & Liu, W. Matrix metalloproteinase-2-mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier damage in early ischemic stroke stage. J Neurosci. 32, 3044-3057 (2012).
29. Ito, D. et al. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res. 57, 1-9 (1998).
30. Nimmerjahn, A., Kirchhoff, F. & Helmchen, F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 308, 1314-1318 (2005).
31. Hains, B. C. & Waxman, S. G. Activated microglia contribute to the maintenance of chronic pain after spinal cord injury. J Neurosci. 26, 4308-4317 (2006).
32. Lu, W. et al. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J Control Release. 107, 428-448 (2005).
33. Ding, D. et al. Bright far-red/near-infrared conjugated polymer nanoparticles for in vivo bioimaging. Small. 9, 3093-3102 (2013).
34. O'Hare Doig, R.L., Bartlett, C.A., Maghzal, G.J., Lam, M., Archer, M., Stocker, R. & Fitzgerald, M. Reactive species and oxidative stress in optic nerve vulnerable to secondary degeneration. Exp Neurol 261, 136-146 (2104).
35. Savigni, D. L., O'Hare Doig, R. L., Szymanski, C. R., Bartlett, C. A., Lozić, I., Smith, N. M. & Fitzgerald, M. Three Ca2+ channel inhibitors in combination reduce chronic secondary degeneration following neurotrauma. Neuropharmacology 75, 380-390 (2013).
36. Lozić, I., Bartlett, C. A., Shaw, J. A., Iyer, K. S., Dunlop, S. A., Kilburn, M. R. & Fitzgerald M. Changes in subtypes of Ca microdomains following partial injury to the central nervous system. Metallomics 6, 455-64 (2014).
37. Kuffler, D. P. Maximizing neuroprotection: where do we stand? Ther. Clin. Risk Manag. 8, 185-194 (2012).